IBRX News

Pomerantz LLP Shares Class Action Details With Investors in ImmunityBio, Inc. – IBRX

Pomerantz LLP Reminds Shareholders with Losses on their Investment in ImmunityBio, Inc. – IBRX

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

ROSEN, SKILLED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

Pomerantz LLP Reminds Shareholders: Securities Lawsuit Has Been Filed Against ImmunityBio, Inc. – IBRX

Pomerantz LLP Reminds Investors: Securities Lawsuit Has Been Filed Against ImmunityBio, Inc. – IBRX

IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 Ready to Announce with Confidence?

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC